Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:
“Dr. Alexander Drilon at CIOT25 clearly favoring taletrectinib as 1L for ROS1 NSCLC – potential and better tox profile. NVL-520 zidesamtinib poised to potentially be best in class. For RET, after selpercatinib or pralsetinib, few options. EP0031 is one in development.”
More posts featuring Stephen V Liu.
